Chatterjee M, Barcos M, Han T, Liu X L, Bernstein Z, Foon K A
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263.
Blood. 1990 Nov 1;76(9):1825-9.
Antiidiotype (Id) antibodies identify unique determinants within the surface immunoglobulin (Ig) that are present on B-cell tumors. Anti-Ids have been used for diagnosis and therapy of B-cell lymphoma and leukemia. A panel of 29 anti-Id monoclonal antibodies (MoAbs) that recognize shared idiotypes (SIds) on B-cell lymphomas was tested for reactivity with both B-cell leukemias and lymphomas. Ten of 40 (25%) cases of chronic lymphocytic leukemia (CLL) reacted with at least one of the 29 anti-SId MoAbs. Three cases reacted with more than one anti-SId MoAb, but there was no repetitive pattern of a single anti-SId MoAb reacting with a large proportion of CLL cases. In contrast, for B-cell lymphoma, in which 11 of 31 (36%) cases reacted, one anti-SId (B4-1) reacted with five of the positive cases; all were diffuse histology. Restricted anti-SId reactivity may lead to important insights into the etiology of certain B-cell lymphomas. In addition, these anti-SIds may obviate the need to develop "tailor-made" antibodies for individual patients.
抗独特型（Id）抗体可识别B细胞肿瘤表面免疫球蛋白（Ig）内存在的独特决定簇。抗Id抗体已用于B细胞淋巴瘤和白血病的诊断与治疗。对一组识别B细胞淋巴瘤上共享独特型（SId）的29种抗Id单克隆抗体（MoAb）进行了检测，以观察其与B细胞白血病和淋巴瘤的反应性。40例慢性淋巴细胞白血病（CLL）中有10例（25%）与29种抗SId MoAb中的至少一种发生反应。3例与不止一种抗SId MoAb发生反应，但不存在单一抗SId MoAb与大部分CLL病例发生反应的重复模式。相比之下，在B细胞淋巴瘤中，31例中有11例（36%）发生反应，一种抗SId（B4-1）与5例阳性病例发生反应；所有病例均为弥漫性组织学类型。抗SId反应性受限可能会为某些B细胞淋巴瘤的病因提供重要见解。此外，这些抗SId抗体可能无需为个体患者研发“量身定制”的抗体。
